Pfizer and Bristol-Myers Squibb have finalized their collaboration agreement to research, develop and commercialize DGAT-1 inhibitors. Pfizer’s DGAT- 1 discovery program includes advanced preclinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes. The program also includes DGAT-1 inhibitors in-licensed by Pfizer from Bayer Pharmaceuticals in June 2006, including a preclinical compound (known as PF-04415060 or BAY 74-4113) orig...